Search research articles
Contact Us
Filters
Showing results (1-10 of 31) with videos related to
Page
of 4
Sort By:
Journal of Lipid Research
|
May 23, 2022
Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial
Rene Rodriguez-Gutierrez, Jose Gerardo González, Deven Parmar, et al.
Clinical Pharmacology in Drug Development
|
November 1, 2023
Pharmacokinetics and Safety Evaluation of Single-Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment
Eric Lawitz, Deven Parmar, Taufik Momin, et al.
Clinical Breast Cancer
|
December 27, 2021
Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) With the Kadcyla (Trastuzumab Emtansine) in the Treatment of HER2-Positive Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India
Satheesh Chiradoni Thungappa, Tanveer Maksud, Nirmal Raut, et al.
Cardiovascular Diabetology
|
June 19, 2019
New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence
Upendra Kaul, Deven Parmar, K Manjunath, et al.
Clinical Pharmacology and Therapeutics
|
October 2, 2024
Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal Impairment
Raj Vuppalanchi, Mary M Cruz, Taufik Momin, et al.
Trials
|
May 9, 2026
Study protocol for a randomized, double-blind, placebo-controlled clinical trial of desidustat oral tablet in sickle cell disease: a phase IIa proof-of-concept evaluation
Mayank Gangwar, Gunjan Kumar, Sudipto Roy, et al.
Clinical Pharmacology in Drug Development
|
December 2, 2022
A Food-Effect Study to Evaluate the Oral Bioavailability of Desidustat
Hardik Patel, Taufik Momin, Kevinkumar Kansagra, et al.
Cardiovascular Diabetology
|
June 21, 2020
Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)
Manjunath Krishnappa, Kishor Patil, Krupi Parmar, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
November 3, 2021
Estimation of ZYKR1 in human urine and plasma utilizing LC-MS/MS positive electrospray ionization; a kappa opioid receptor (KOR) agonist
Ashok Ghoghari, Chandrakant Bhatt, Kuldip Patel, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
June 13, 2025
A phase 2, proof-of-concept, placebo-controlled, randomized, multicenter, double-blind study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of Usnoflast (ZYIL1) in patients with amyotrophic lateral sclerosis
Amit Yeole, Laxmi Khanna, Maulik Doshi, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 31) with videos related to
Sort By:
Page
of 4
Journal of Lipid Research
|
May 23, 2022
Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial
Rene Rodriguez-Gutierrez, Jose Gerardo González, Deven Parmar, et al.
Clinical Pharmacology in Drug Development
|
November 1, 2023
Pharmacokinetics and Safety Evaluation of Single-Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment
Eric Lawitz, Deven Parmar, Taufik Momin, et al.
Clinical Breast Cancer
|
December 27, 2021
Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) With the Kadcyla (Trastuzumab Emtansine) in the Treatment of HER2-Positive Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India
Satheesh Chiradoni Thungappa, Tanveer Maksud, Nirmal Raut, et al.
Cardiovascular Diabetology
|
June 19, 2019
New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence
Upendra Kaul, Deven Parmar, K Manjunath, et al.
Clinical Pharmacology and Therapeutics
|
October 2, 2024
Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal Impairment
Raj Vuppalanchi, Mary M Cruz, Taufik Momin, et al.
Trials
|
May 9, 2026
Study protocol for a randomized, double-blind, placebo-controlled clinical trial of desidustat oral tablet in sickle cell disease: a phase IIa proof-of-concept evaluation
Mayank Gangwar, Gunjan Kumar, Sudipto Roy, et al.
Clinical Pharmacology in Drug Development
|
December 2, 2022
A Food-Effect Study to Evaluate the Oral Bioavailability of Desidustat
Hardik Patel, Taufik Momin, Kevinkumar Kansagra, et al.
Cardiovascular Diabetology
|
June 21, 2020
Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)
Manjunath Krishnappa, Kishor Patil, Krupi Parmar, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
November 3, 2021
Estimation of ZYKR1 in human urine and plasma utilizing LC-MS/MS positive electrospray ionization; a kappa opioid receptor (KOR) agonist
Ashok Ghoghari, Chandrakant Bhatt, Kuldip Patel, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
June 13, 2025
A phase 2, proof-of-concept, placebo-controlled, randomized, multicenter, double-blind study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of Usnoflast (ZYIL1) in patients with amyotrophic lateral sclerosis
Amit Yeole, Laxmi Khanna, Maulik Doshi, et al.
Page
of 4